de Jong EMGJ - Search Results

1

Highlights of the updated Dutch evidence- and consensus-based guideline on psoriasis 2017.

van der Kraaij GE, Balak DMW, Busard CI, van Cranenburgh OD, Chung Y, Driessen RJB, de Groot M, de Jong EMGJ, Kemperman PMJH, de Kort WJA, Karsch SA, Lamberts A, Lecluse LLA, van Lümig PPM, Menting SP, Prens EP, van den Reek JMPA, Seyger MMB, Thio HB, Veldkamp WR, Wakkee M, Nast A, Jacobs A, Rosumeck S, Spuls Chair PI. van der Kraaij GE, et al. Among authors: de jong emgj, de groot m, de kort wja. Br J Dermatol. 2019 Jan;180(1):31-42. doi: 10.1111/bjd.17198. Br J Dermatol. 2019. PMID: 30604536 Free PMC article.

2

Markers for proliferation and keratinization in the margin of the active psoriatic lesion.

de Mare S, de Jong E, Van Erp PE, Van de Kerkhof PC. de Mare S, et al. Br J Dermatol. 1990 Apr;122(4):469-75. doi: 10.1111/j.1365-2133.1990.tb14723.x. Br J Dermatol. 1990. PMID: 1692474

3

Simultaneous assessment of inflammation and epidermal proliferation in psoriatic plaques during long-term treatment with the vitamin D3 analogue MC903: modulations and interrelations.

de Jong EM, van de Kerkhof PC. de Jong EM, et al. Br J Dermatol. 1991 Mar;124(3):221-9. doi: 10.1111/j.1365-2133.1991.tb00565.x. Br J Dermatol. 1991. PMID: 2018728 Clinical Trial.

4

Altered distribution of heparan sulfate proteoglycans in psoriasis.

Seyger MM, van den Born J, Schalkwijk J, van de Kerkhof PC, de Jong EM. Seyger MM, et al. Acta Derm Venereol. 1997 Mar;77(2):105-9. doi: 10.2340/0001555577105109. Acta Derm Venereol. 1997. PMID: 9111818 Free article. Clinical Trial.

5

Epicutaneous application of leukotriene B4 induces patterns of tenascin and a heparan sulfate proteoglycan epitope that are typical for psoriatic lesions.

Seyger MM, van Pelt JP, van den Born J, Latijnhouwers MA, de Jong EM. Seyger MM, et al. Arch Dermatol Res. 1997 May;289(6):331-6. doi: 10.1007/s004030050200. Arch Dermatol Res. 1997. PMID: 9209678 Free article.

6

Extremely low levels of epidermal skin-derived antileucoproteinase/elafin in a patient with impetigo herpetiformis.

Kuijpers AL, Schalkwijk J, Rulo HF, Peperkamp JJ, van de Kerkhof PC, de Jong EM. Kuijpers AL, et al. Br J Dermatol. 1997 Jul;137(1):123-9. Br J Dermatol. 1997. PMID: 9274639

7

The course of psoriasis.

de Jong EM. de Jong EM. Clin Dermatol. 1997 Sep-Oct;15(5):687-92. doi: 10.1016/s0738-081x(97)00023-0. Clin Dermatol. 1997. PMID: 9313967 Review. No abstract available.

8

Reliability of two methods to assess morphea: skin scoring and the use of a durometer.

Seyger MM, van den Hoogen FH, de Boo T, de Jong EM. Seyger MM, et al. J Am Acad Dermatol. 1997 Nov;37(5 Pt 1):793-6. doi: 10.1016/s0190-9622(97)70121-x. J Am Acad Dermatol. 1997. PMID: 9366834 Free article. Clinical Trial. No abstract available.

9

Low-dose methotrexate in the treatment of widespread morphea.

Seyger MM, van den Hoogen FH, de Boo T, de Jong EM. Seyger MM, et al. J Am Acad Dermatol. 1998 Aug;39(2 Pt 1):220-5. doi: 10.1016/s0190-9622(98)70079-9. J Am Acad Dermatol. 1998. PMID: 9704833 Clinical Trial.

10

The efficacy of a new topical treatment for psoriasis: Mirak.

Seyger MM, van de Kerkhof PC, van Vlijmen-Willems IM, de Bakker ES, Zwiers F, de Jong EM. Seyger MM, et al. J Eur Acad Dermatol Venereol. 1998 Jul;11(1):13-8. J Eur Acad Dermatol Venereol. 1998. PMID: 9731960 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

315 results

Search Page

Filters